Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”
Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.
How this was made
The 30-second read
Why it matters
The earnings beat and forward guidance provide a fresh catalyst for traders, while margin and concentration risks temper enthusiasm.
Market read
Cardinal Health's earnings and guidance are likely to move the stock and influence the broader health‑care distribution sector.
What to watch
High customer concentration—CVS accounts for 28% of revenue—adds execution risk not fully priced in.
Background
Jim Cramer highlighted Cardinal Health as a top pick, emphasizing its shift toward higher‑margin services and recent acquisitions.
Ticker impact
Cardinal Health reported Q4 revenue of $63.7B and issued FY 2027 non‑GAAP EPS guidance of $12.40‑$12.60, a fresh earnings disclosure.
Potential upside of 5‑10% if guidance is accepted; downside risk if specialty growth stalls.
New guidance is material for a large cap distributor; market will price in higher earnings expectations while monitoring margin pressure.
Market effects
Healthcare distribution sector may see valuation adjustments as Cardinal Health's specialty shift sets a benchmark.
U.S. equity markets, especially health‑care indices, could react to the guidance.
Global pharma supply chains may be influenced by Cardinal's at‑home medical‑supply expansion.
Counterpoint
The stock may be overvalued at a forward P/E of 19; a slowdown in specialty growth could trigger a sharp reset.
Key entities
- companyCardinal Health, Inc.
U.S. healthcare distributor providing specialty pharmaceuticals and services.
